Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858111 | 1.00 | HSD17B10 (1.00) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL20564592 | 0.98 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL3873222 | 0.98 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL15935 | 0.98 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL9193218 | 0.98 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL24368139 | 0.95 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL15572293 | 0.95 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL2910021 | 0.95 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| Hydrochloric Acid SCHEMBL1128463 | 0.95 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL15572644 | 0.95 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235227-B2 | Paramagnetic particles that provide improved relaxivity | BARNES-JEWISH HOSPITAL (US) | 2007-06-26 | — | — | US | claimed |
| US-6869591-B2 | Paramagnetic particles that provide improved relaxivity | BARNES-JEWISH HOSPITAL (US) | 2005-03-22 | — | — | US | claimed |
| US-20030215392-A1 | Paramagnetic particles that provide improved relaxivity | KEREOS, INC. | 2003-11-20 | — | — | US | claimed |
| US-20030185760-A1 | Paramagnetic particles that provide improved relaxivity | KEREOS, INC. | 2003-10-02 | — | — | US | claimed |
| US-4215000-A | CROWN ETHER COMPLEXES; RAPID REACTION | SHELL DEVELOPMENT COMPANY (US) | 1980-07-29 | — | — | US | claimed |
| CN-115799614-A | Secondary battery | 珠海冠宇电池股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-9243031-B2 | Complex-forming compounds | STRATOXER(S) KFT. (HU) | 2016-01-26 | — | — | US | disclosed |
| US-9243031-B2 | Complex-forming compounds | STRATOXER(S) KFT. (HU) | 2016-01-26 | — | — | US | disclosed |
| US-20140342997-A1 | COMPLEX-FORMING COMPOUNDS | STRATOXER(S) KFT. (HU) | 2014-11-20 | — | — | US | disclosed |
| US-20140342997-A1 | COMPLEX-FORMING COMPOUNDS | STRATOXER(S) KFT. (HU) | 2014-11-20 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| WO-1993014093-A1 | METAL COMPLEXES OF WATER SOLUBLE TEXAPHYRINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5162509-A | Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0462206-A1 | EXPANDED PORPHYRINS: LARGE PORPHYRIN-LIKE TRIPYRROLEDIMETHINE-DERIVED MACROCYCLES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0426824-A1 | METHOD FOR THE PREPARATION OF ACTIVE INGREDIENTS AND PHARMACEUTICAL COMPOSITIONS FOR DECORPORATING RADIOACTIVE ISOTOPES FROM LIVING ORGANISMS | ORSZAGOS "FREDERIC JOLIOT-CURIE" SUGARBIOLOGIA ES SUGAREGESZSEGUGYI KUTATO INTEZET (HU) | 1991-05-15 | — | — | EP | disclosed |
| WO-1990014343-A1 | METHOD FOR THE PREPARATION OF ACTIVE INGREDIENTS AND PHARMACEUTICAL COMPOSITIONS FOR DECORPORATING RADIOACTIVE ISOTOPES FROM LIVING ORGANISMS | ORSZÁGOS 'FREDERIC JOLIOT-CURIE' SUGÁRBIOLÓGIAI ÉS SUGÁREGÉSZSÉGÜGYI KUTATÓ INTÉZET (HU) | 1990-11-29 | — | — | WO | disclosed |
| WO-1990010633-A1 | EXPANDED PORPHYRINS: LARGE PORPHYRIN-LIKE TRIPYRROLEDIMETHINE-DERIVED MACROCYCLES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-09-20 | — | — | WO | disclosed |
| US-4935498-A | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-06-19 | — | — | US | disclosed |
| US-4215000-A | CROWN ETHER COMPLEXES; RAPID REACTION | SHELL DEVELOPMENT COMPANY (US) | 1980-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | HSD17B10 3512/4885KDM4E 2225/4885ALOX15 1960/4885 |
| US-20140342997-A1 | COMPLEX-FORMING COMPOUNDS | F2, CYP2F1, CYP4F2 | HSD17B10 498/4885KDM4E 4486/4885ALOX15 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.